Müller S, Schütt P, Bojko P, Nowrousian M R, Hense J, Seeber S, Moritz T
Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Duisburg-Essen Medical School, Hufelandstr. 55, 45122, Essen, Germany.
Ann Hematol. 2005 Feb;84(2):110-4. doi: 10.1007/s00277-004-0938-8. Epub 2004 Sep 1.
Hemolytic uremic syndrome (HUS) has been described following the administration of multiple antineoplastic agents, most notably mitomycin C. More recently, several cases of gemcitabine-induced HUS have been observed with the overall incidence of gemcitabine-induced HUS estimated at 0.015-0.25%. We here report on four patients who developed HUS following gemcitabine therapy at our institution within the last year (incidence 1.4%). All these patients had advanced-stage disease, were heavily pretreated, and received prolonged gemcitabine application, suggesting that in this subgroup of patients HUS may be more frequently encountered than documented so far.
溶血性尿毒症综合征（HUS）已在多种抗肿瘤药物给药后被描述，最显著的是丝裂霉素C。最近，已观察到几例吉西他滨诱导的HUS病例，吉西他滨诱导的HUS总体发生率估计为0.015%-0.25%。我们在此报告去年在我们机构接受吉西他滨治疗后发生HUS的4例患者（发生率1.4%）。所有这些患者均为晚期疾病，接受过大量预处理，并长期应用吉西他滨，这表明在这一亚组患者中，HUS可能比迄今记录的更频繁地出现。
